Direkt zum Inhalt
Merck
  • Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country.

Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country.

Pediatric blood & cancer (2014-09-02)
Sapna Oberoi, Amita Trehan, Ram Kumar Marwaha
ZUSAMMENFASSUNG

Medication errors occur universally. Inappropriate administration of chemotherapy drugs can have adverse effects in cancer patients. Our objective was to assess the rate and type of medication errors in children with acute lymphoblastic leukemia (ALL) receiving oral chemotherapy in outpatient setting. Prescription and administration of oral chemotherapy drugs in children with ALL were evaluated prospectively to determine rate and type of medication errors. Errors were defined as prescription (physician) level or administration (patient) level errors. Two hundred eighty-nine drugs were prescribed to 121 patients. Medication errors occurred in 36 (12.5%) prescriptions; 21(7.3%) were administration errors, 13 (4.5%) were prescribing errors, and two errors occurred at both levels. Mercaptopurine (6-MP) was significantly associated with higher rates of errors (Odds ratio [OR] = 2.1, 95% CI [confidence interval] 1-4.1) whereas lapses were less with dexamethasone (OR = 0.25, 95% CI 0.09-0.67). As a result of medication errors 28 (23.1%) patients received inappropriate doses. Twenty five (21%) patients received sub-optimal doses whereas three got higher doses of chemotherapy. On univariate analysis, socioeconomic status, education status of the caregiver, 6-MP and methotrexate were significantly associated with errors (P ≤ 0.05). On multivariate analysis, ≤ primary school education of the caregiver and prescription of methotrexate were independent predictors of errors. Medication errors affected nearly one fourth of the children receiving oral chemotherapy. Future studies are needed to look at effective interventions to avoid chemotherapy associated errors especially amongst the lower strata of society.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethason – wasserlöslich, suitable for cell culture, BioReagent
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
SAFC
Methotrexat
Sigma-Aldrich
L-Amethopterin Hydrat, ≥98% (HPLC), powder
Sigma-Aldrich
L-Amethopterin Hydrat, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Methotrexat -Lösung, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
6-Mercaptopurin Monohydrat, 98%
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Methotrexat, meets USP testing specifications
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Supelco
Methotrexat, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Amethopterin Hydrat, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Methotrexat, European Pharmacopoeia (EP) Reference Standard
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethason, VETRANAL®, analytical standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Methotrexat für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Methotrexat für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard